ASPN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aspen Aerogels Inc (ASPN) is not a good buy for a beginner investor with a long-term strategy at this time. The company's financial performance is significantly weak, with declining revenue, net income, and EPS. Analysts have lowered price targets, and there are no positive trading signals or recent news to support a bullish case. Additionally, insider selling has increased substantially, and technical indicators suggest a bearish trend. While there is a potential for short-term price recovery, the long-term outlook remains uncertain.
The MACD is below zero and negatively contracting, indicating bearish momentum. RSI is neutral at 53.018, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels suggest limited upside potential, with the stock trading near its pivot point of 3.588.
NULL identified. No recent news or significant positive developments.
Weak financial performance in Q4 2025, with revenue down -66.42% YoY and net income down -741.73% YoY.
Insider selling increased by 288.04% over the last month.
Analysts have lowered price targets and highlighted challenges in the EV market and demand reset for key customer GM.
In Q4 2025, revenue dropped to $41.34M (-66.42% YoY), net income dropped to -$72.91M (-741.73% YoY), EPS dropped to -0.88 (-728.57% YoY), and gross margin dropped to -55.47 (-244.87% YoY).
Analysts have lowered price targets significantly: Barclays to $3 (Underweight), Roth Capital to $3 (Buy), B. Riley to $4 (Buy), and TD Cowen to $6 (Buy). Analysts cite challenges in the EV market and weak near-term visibility but acknowledge potential long-term opportunities.
